The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 23, 2020

Filed:

Mar. 30, 2015
Applicant:

Boehringer Ingelheim Vetmedica Gmbh, Ingelheim am Rhein, DE;

Inventors:

Dania Birte Reiche, Bingen am Rhein, DE;

Nicole Mohren, Jugenheim, DE;

Laura Johnston, Thornleigh, AU;

Bruce Somerville, Parkville, MO (US);

Rebecca K. Voth, Smithville, MO (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 5/50 (2006.01); C07D 309/10 (2006.01); A61P 3/10 (2006.01); A61K 31/351 (2006.01); A61K 31/7034 (2006.01); A61K 31/7042 (2006.01); A61K 31/7048 (2006.01); A61K 31/7056 (2006.01); A61K 47/02 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 9/02 (2006.01); A61K 9/08 (2006.01); A61K 31/382 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7034 (2013.01); A61K 9/02 (2013.01); A61K 9/08 (2013.01); A61K 9/2059 (2013.01); A61K 9/4866 (2013.01); A61K 31/351 (2013.01); A61K 31/382 (2013.01); A61K 31/7042 (2013.01); A61K 31/7048 (2013.01); A61K 31/7056 (2013.01); A61K 47/02 (2013.01); A61P 3/10 (2018.01); A61P 5/50 (2018.01); C07D 309/10 (2013.01);
Abstract

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and/or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and/or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and/or Equine Metabolic Syndrome in an equine animal.


Find Patent Forward Citations

Loading…